Extended prophylaxis of venous thromboembolism with idraparinux

Article Abstract:

The efficiency and the safety of a continuous use of vitamin K for prophylaxis against the venous thromboembolism with idraparinux in various patients were examined. The results showed that though idraparinux helps in preventing recurrent thromboembolism, it also increases the risks of a major hemorrhage.

Risk factors, Hemorrhage, Vitamin K

---

Idraparinux versus standard therapy for venous thromboembolic disease

Article Abstract:

The use of idraparinux, a long-acting inhibitor of activated factor X, instead of the standard therapy of treating the venous thromboembolic disease is investigated. The analysis reveals that idraparinux is less effective than the standard therapy for patients with pulmonary embolism.

United States, Pharmaceutical Preparation Manufacturing, Pharmaceutical preparations, Anticoagulant Preparations, Drug therapy, Anticoagulants (Medicine), Anticoagulants

---

Similar abstracts:

• Abstracts: Oral anticoagulant therapy for venous thromboembolism. Secondary prophylaxis with warfarin for venous thromboembolism
• Abstracts: The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. Psychiatric hospitalizations among survivors of cancer in childhood or adolescence
• Abstracts: Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis
• Abstracts: Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction
• Abstracts: A charter for life. Open access transforms care

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.